Details of the Drug Combination

General Information of Drug Combination (ID: DCSNOA3)

Drug Combination Name
JNK-IN-8 Valrubicin
Indication
Disease Entry Status REF
Childhood T acute lymphoblastic leukemia Investigative [1]
Component Drugs JNK-IN-8   DMLWYJB Valrubicin   DMOYJFK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: CCRF-CEM
Zero Interaction Potency (ZIP) Score: 3.94
Bliss Independence Score: 1.86
Loewe Additivity Score: 1.26
LHighest Single Agent (HSA) Score: 2.39

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JNK-IN-8
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JNK-IN-8 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [2]
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
JNK-IN-8 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of Valrubicin
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Approved [3]
In situ carcinoma N.A. Approved [4]
Urinary bladder cancer N.A. Approved [4]
Psoriasis vulgaris EA90 Phase 2 [5]
Valrubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Valrubicin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCXIS4L HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DC9GXZF MOLT-4 Investigative [1]
Renal cell carcinoma DCMU4YJ SN12C Investigative [1]
Lung adenocarcinoma DC2RNEK EKVX Investigative [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Valrubicin FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 A H2AX?CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage. Cancers (Basel). 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221.
7 Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
8 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
9 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.